Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen Inks Deal with Biogen Idec to Explore Companion Dx for Drug Candidate

Premium

Asuragen said this week that it has signed a deal to work with Biogen Idec to identify "a potential companion diagnostic test" that may be used to choose patients likely to respond to an undisclosed Biogen Idec drug currently in clinical development.

“The integrated drug-diagnostic co-development strategy being pursued by Biogen Idec and Asuragen has enormous potential to help physicians identify patients that will benefit from specific cancer treatments, and will be another step towards delivering on the promise of personalized medicine,” Asuragen CEO Matt Winkler said in a statement.

Additional terms of the deal were not disclosed.

It was not clear whether the potential diagnostic would be based on microRNA expression patterns. Last year, Asuragen began marketing an miRNA-based test for differentiating pancreatitis from pancreatic ductal adenocarcinoma (see RNAi News, 5/2/2008).

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.